PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1lowincrease tumor angiogenesis

Description

Cancer stem-like cells are proposed to sustain solid tumors by virtue of their capacity for self-renewal and differentiation to cells that comprise the bulk of the tumor, and have been identified for a variety of cancers based on characteristic clonal morphologies and patterns of marker gene expression. Methods Single cell cloning and spheroid culture studies were used to identify a population of cancer stem-like cells in the androgen-independent human prostate cancer cell line PC3. Results We demonstrate that, under standard culture conditions, ~10% of PC3 cells form holoclones with cancer stem cell characteristics. These holoclones display high self-renewal capability in spheroid formation assays under low attachment and serum-free culture conditions, retain their holoclone morphology when passaged at high cell density, exhibit moderate drug resistance, and show high tumorigenicity in scid immunodeficient mice. PC3 holoclones readily form spheres, and PC3-derived spheres yield a high percentage of holoclones, further supporting their cancer stem cell-like nature. We identified one gene, FAM65B , whose expression is consistently up regulated in PC3 holoclones compared to paraclones, the major cell morphology in the parental PC3 cell population, and two genes, MFI2 and LEF1 , that are consistently down regulated. This molecular profile, FAM65B high /MFI2 low /LEF1 low , also characterizes spheres generated from parental PC3 cells. The PC3 holoclones did not show significant enriched expression of the putative prostate cancer stem cell markers CD44 and integrin α2β1. PC3 tumors seeded with holoclones showed dramatic down regulation of FAM65B and dramatic up regulation of MFI2 and LEF1 , and unexpectedly, a marked increase in tumor vascularity compared to parental PC3 tumors, suggesting a role of cancer stem cells in tumor angiogenesis. Conclusions These findings support the proposal that PC3 tumors are sustained by a small number of tumor-initiating cells with stem-like characteristics, including strong self-renewal and pro-angiogenic capability and marked by the expression pattern FAM65B high /MFI2 low /LEF1 low . These markers may serve as targets for therapies designed to eliminate cancer stem cell populations associated with aggressive, androgen-independent prostate tumors such as PC3.

Subjects

• Documents
• Knowledge

Informations

• Published by: biomed
• Published: 01 January 2010
• Reads: 23
• Language: English

Exrait

Zhang and WaxmanMolecular Cancer2010,9:319 http://www.molecularcancer.com/content/9/1/319

R E S E A R C HOpen Access PC3 prostate tumorinitiating cells with molecular high lowlow profile FAM65B/MFI2 /LEF1increase tumor angiogenesis * Kexiong Zhang, David J Waxman

Abstract Background:Cancer stemlike cells are proposed to sustain solid tumors by virtue of their capacity for selfrenewal and differentiation to cells that comprise the bulk of the tumor, and have been identified for a variety of cancers based on characteristic clonal morphologies and patterns of marker gene expression. Methods:Single cell cloning and spheroid culture studies were used to identify a population of cancer stemlike cells in the androgenindependent human prostate cancer cell line PC3. Results:We demonstrate that, under standard culture conditions, ~10% of PC3 cells form holoclones with cancer stem cell characteristics. These holoclones display high selfrenewal capability in spheroid formation assays under low attachment and serumfree culture conditions, retain their holoclone morphology when passaged at high cell density, exhibit moderate drug resistance, and show high tumorigenicity in scid immunodeficient mice. PC3 holoclones readily form spheres, and PC3derived spheres yield a high percentage of holoclones, further supporting their cancer stem celllike nature. We identified one gene,FAM65B, whose expression is consistently up regulated in PC3 holoclones compared to paraclones, the major cell morphology in the parental PC3 cell population, and two genes,MFI2andLEF1, that are consistently down regulated. This molecular profile, high low low FAM65B /MFI2/LEF1 ,also characterizes spheres generated from parental PC3 cells. The PC3 holoclones did not show significant enriched expression of the putative prostate cancer stem cell markers CD44 and integrin a2b1. PC3 tumors seeded with holoclones showed dramatic down regulation ofFAM65Band dramatic up regulation ofMFI2andLEF1, and unexpectedly, a marked increase in tumor vascularity compared to parental PC3 tumors, suggesting a role of cancer stem cells in tumor angiogenesis. Conclusions:These findings support the proposal that PC3 tumors are sustained by a small number of tumor initiating cells with stemlike characteristics, including strong selfrenewal and proangiogenic capability and high lowlow marked by the expression pattern/LEF1FAM65B /MFI2. These markers may serve as targets for therapies designed to eliminate cancer stem cell populations associated with aggressive, androgenindependent prostate tumors such as PC3.

Background Solid tumors are proposed to be sustained by a limited number of cancer stemlike cells (CSCs) with high poten tial for proliferation and the capacity to differentiate into cells that comprise the bulk of the tumor [1]. Tumors may be maintained by a hierarchical organization of rare CSCs, rapidly dividing cells, and differentiated tumor

* Correspondence: [e-mail] Division of Cell and Molecular Biology, Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA

cells [2,3]. CSCs are regarded as important for tumor progression, metastasis and tumor recurrence due to their strong selfrenewing capability and resistance to certain cancer chemotherapeutic drugs. Consequently, conventional cancer therapies that eliminate the bulk of a tumor may fail to eliminate CSCs [4,5]. Elucidating the biological properties of CSCs can provide insight into the factors that drive tumor initiation and progression and may help to increase therapeutic responses, overcome drug resistance and develop novel cancer treatments with low systemic toxicity [2,6]. CSCs express characteristic

© 2010 Zhang and Waxman; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.